Calyxo Enters AUA2026 With Its Largest Clinical Evidence Presence to Date and Enhanced Visualization
Calyxo, Inc. will showcase its CVIC System at the American Urological Association’s 2026 meeting, presenting a record ten abstracts that highlight safety, efficacy, and procedural efficiency. The company reports that more than 40,000 patients have been treated with the CVIC System since its 2024 FDA clearance. At the conference, Calyxo will debut CVIC Image Processor Software version 1.5, which delivers clearer, more consistent intra‑operative imaging. A robust schedule of hands‑on workshops and peer‑to‑peer sessions will give urologists direct experience with the technology.
Seven Northwell Hospitals Earn CMS 5-Star Ratings
Northwell Health announced that seven of its hospitals earned the highest five‑star rating from the Centers for Medicare & Medicaid Services (CMS) in the 2026 Star Quality Rating System, while five additional facilities received four‑star ratings. This marks the first...
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences announced the issuance of U.S. Patent No. 12,605,361 covering its carboxylated psilocybin‑derived EVM301 series for treating psychiatric disorders. The new patent expands the company’s intellectual‑property moat by protecting method claims that build on its earlier patent (No. 11,752,130). Enveric is...
Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing
Elpida Therapeutics and contract manufacturer Catalent have entered a strategic partnership to handle late‑phase manufacturing of Elpida’s lead AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Catalent will also receive exclusive rights to produce Elpida’s other adeno‑associated virus (AAV) programs,...
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
CEL‑SCI Corp. has signed a strategic partnership with Saudi firm Amarox to register, commercialize, and distribute its immunotherapy Multikine in Saudi Arabia, with a 50/50 revenue‑sharing model. Amarox will act as the local regulatory representative, seeking the Saudi Food and...
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic’s Aptima HPV Assay
OM1’s AI‑driven real‑world evidence platform underpinned a landmark FDA submission that cleared Hologic’s Aptima HPV assay for primary cervical cancer screening. The study aggregated data from more than 650,000 women across U.S. health systems, automating extraction from electronic health records...
Health Info Net Advances Sovereign Digital Healthcare With Red Hat and VSHN
Health Info Net (HIN) partnered with Red Hat and managed‑service provider VSHN to migrate its IT services to a multivendor private‑cloud built on Red Hat OpenShift. The new sovereign infrastructure, spanning Swiss clouds Cloudscale and Exoscale, was stood up in 36 hours and...
Iambic to Participate in Upcoming Investor Conferences
Iambic, a clinical‑stage life‑science firm that uses AI to discover medicines, announced its participation in three high‑profile investor events: the Bank of America Healthcare Conference (May 12‑14), the Jefferies Global Healthcare Conference (June 2‑4) and the Bank of America Technology Conference (June 2‑4)....
Avenacy Announces Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S. Market
Avenacy, a specialty injectable drug company, has launched a ready‑to‑use Tranexamic Acid 0.7% Sodium Chloride Injection in the United States. The product mirrors the active ingredient of Pfizer’s CYKLOKAPRON® and is indicated for short‑term use in hemophilia patients undergoing tooth...
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors
HistoSonics has filed a De Novo request with the FDA to expand its Edison® Histotripsy System from liver to kidney tumor treatment. The submission is backed by the ongoing HOPE4KIDNEY trial, which has enrolled 67 patients and shows precise, non‑invasive tumor...
The Vitamin Shoppe to Add Shakeology by BODi in Retail Locations Nationwide
BODi announced that its flagship nutrition drink Shakeology will roll out in all 640 Vitamin Shoppe stores later this year, adding a seven‑serving bag format priced at $34.99. The launch follows a recent debut in more than 80 Sprouts locations and...
Media Advisory: Surescripts to Highlight Smarter Health Intelligence Sharing That Helps Close Gaps in Patient Care at AHIP 2026
Surescripts, the leading health intelligence network, will speak at AHIP 2026 in Las Vegas about using smarter data sharing to close care gaps. Interoperability experts Justin McMartin and Matt Hartzler will detail how linking health‑plan data with pharmacy‑fill and clinical records can pinpoint adherence...
Therorna to Showcase Clinical-Ready Circular RNA in Vivo CAR-T and CircRNA Pipeline at the 2026 American Society of Gene &...
Therorna Inc. will present three posters at the 2026 ASGCT meeting, highlighting its lead in‑vivo CAR‑T candidate TI‑0032, a circRNA‑encoded CD19×CD3 T‑cell engager, and the HPV16 therapeutic vaccine TI‑0093. TI‑0032 has just entered a first‑in‑human investigator‑initiated trial for refractory autoimmune...
Saban Community Clinic Breaks Ground on Crenshaw Family Health Center, Expanding Access For Over 287,000 Low-Income People in One of...
Saban Community Clinic broke ground on the Crenshaw Family Health Center, a two‑story facility in South Los Angeles that will serve more than 287,000 low‑income residents. The center will deliver medical, dental, behavioral health and pharmacy services under one roof,...
Bruno Vision Care Wins 2026 MedTech Breakthrough Award
Bruno Vision Care’s Deseyne® daily‑disposable contact lens, the first FDA‑cleared Extended Depth of Focus (EDOF) lens for presbyopia, won the 2026 MedTech Breakthrough Award for Best New Technology Solution – Ophthalmology. The lens uses a patented hyper‑refractive central zone and...
Smart Hospitals Market to Reach $363.9 Billion by 2032, DataM Intelligence Reports, Driven by AI Clinical Workflows and Connected Care
DataM Intelligence projects the global smart‑hospital market to expand from $58.2 billion in 2024 to $363.9 billion by 2032, a 26.2% compound annual growth rate. The surge is driven by AI‑enabled clinical workflows, connected patient rooms, and remote monitoring that move health...
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
WHOOP unveiled a suite of health‑focused upgrades, adding on‑demand video consultations with licensed clinicians and EHR syncing through HealthEx, slated for a U.S. launch this summer. The platform also introduced two AI tools—My Memory, which lets members edit personal context,...
Kanvas Biosciences Receives New Funding to Develop First-In-Category Microbiome Therapeutic for Improving Maternal, Newborn and Child Health
Kanvas Biosciences announced a new investment from the Gates Foundation to develop the world’s first fully synthetic microbiome therapeutic targeting maternal environmental enteric dysfunction (EED). The product will use a complex, multi‑strain consortium designed with AI‑driven discovery and spatial microbiome...
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
Assertio Holdings and Garda Therapeutics have mutually agreed to postpone the tender offer for Assertio’s acquisition to May 14, 2026. The original agreement valued the transaction at $21.80 per share, or roughly $153.2 million in cash. Both the cash tender for common shares...
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
STAAR Low‑Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology have launched the LGSOC Resource Guide on World Ovarian Cancer Day. The guide aggregates trusted educational content, videos, and FAQs to help patients, caregivers, and advocates navigate diagnosis,...
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment...
Vistagen announced that the final participant has finished the randomized, double‑blind portion of its Phase 3 PALISADE‑4 trial evaluating fasedienol nasal spray for acute social anxiety disorder. The company expects to release topline efficacy and safety data in the second quarter...
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences (NASDAQ: PLSE) announced it will present at the Bank of America Securities 2026 Healthcare Conference in Las Vegas on May 13. The company will showcase its proprietary nPulse™ nanosecond pulsed field ablation (nsPFA™) platform, which aims to treat...
Herbalife and Cristiano Ronaldo Bring Performance Nutrition to Everyday Routines with “Fuel Like Ronaldo” Campaign
Herbalife Ltd. announced the global “Fuel Like Ronaldo” campaign, turning elite‑athlete nutrition into a four‑step daily framework for everyday wellness seekers. The initiative leverages the company’s 20‑year partnership with Cristiano Ronaldo, featuring a signature shake, digital tools, and personalized nutrition platforms....
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (Deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis, either as monotherapy or with methotrexate. The approval follows positive Phase 3 POETYK PsA‑1 and POETYK PsA‑2 trials, which demonstrated statistically significant improvements in ACR20...
Veradigm Survey: Independent Practices Rely on Technology to Stay Independent
Veradigm’s March 2026 survey of 360 independent practice leaders shows that 79% view technology as essential to maintaining independence amid rising costs and administrative pressure. Over half (57%) say better automation would markedly improve performance, while 68% admit limited real‑time...
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
Waiv, the Paris‑based AI precision‑testing firm formerly known as Owkin Dx, has partnered with Daiichi Sankyo to lead digital pathology biomarker discovery for an antibody‑drug conjugate (ADC) program. The collaboration will apply Waiv’s end‑to‑end computational pathology platform to early‑phase trial data,...
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing Into Clinical Workflows
Lucent Diagnostics, a Quanterix brand, partnered with Tempus AI to embed its LucentAD® Complete blood‑based Alzheimer’s biomarker panel into Tempus’ clinical ordering platform. The collaboration creates a Tempus Next care‑gap program that automatically identifies patients who meet guideline criteria for...
Tenet to Participate in the BofA Securities Health Care Conference
Tenet Healthcare Corp. (NYSE:THC) will present at the Bank of America Securities Health Care Conference on May 13, 2026, at 6:00 p.m. ET. The session will be streamed live and archived for 30 days on Tenet’s investor‑relations website. The appearance gives...
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
Simulations Plus announced a technical collaboration with NVIDIA to embed GPU‑accelerated and AI‑assisted modeling into drug‑development workflows. The partnership will re‑engineer Simulations Plus’ PBPK, PK/PD and QSP engines for NVIDIA GPUs, delivering up to a 75% reduction in simulation runtimes...
Most Oncology Brands Lose Before Launch Day — New ZoomRx Analysis of 40+ Drugs Quantifies the Awareness Gap That Predicts...
ZoomRx’s 2026 "Laggards and Leaders" analysis of 44 oncology brands shows that pre‑launch physician awareness drives commercial success. Brands entering the market with about 75% aided awareness outperform those starting at 55%, a 25‑point gap that persists through four years....
HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Wins Silver 2026 Edison Award
HemoSonics' Quantra® Hemostasis System for obstetric procedures earned the Silver Edison Award in the Women’s Health and Reproductive Innovations category for 2026. The device is the first FDA‑cleared viscoelastic testing platform specifically approved for obstetric bleeding, delivering whole‑blood coagulation results...
Magnus Expands Access to 5-Day SAINT® Depression Therapy as Leading Health Systems Scale Nationwide Adoption
Magnus Medical announced that its FDA‑cleared SAINT® rapid‑remission depression therapy is expanding to 14 states, adding partners such as Cleveland Clinic, UPMC and HCA Healthcare. Payer reimbursement now covers more than 80 million lives, including Medicare fee‑for‑service and several commercial plans....
Pediatrica Health Group Acquires Miami Practice, Expanding and Enhancing Equitable Access to Care as Population Growth Soars
Pediatrica Health Group announced the acquisition of a Westchester‑Miami pediatric practice, adding a new location to its multi‑site network. The deal brings Dr. Juan Ruiz‑Unger’s four‑decade legacy under Pediatrica’s umbrella, while a new APRN, Javier Torres Hernandez, expands clinical capacity....
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT
Bracco Imaging announced an Early Access Program for its new BubbleGen™ technology, which uses buoyant microbubbles to isolate and activate specific cell subtypes. The platform offers a one‑step, magnetic‑residue‑free alternative to traditional bead‑based cell separation, initially demonstrated with CD3⁺ T‑cell selection...
Most Workers Say Menopause Shouldn’t Be Ignored at Work
A Harris Poll commissioned by Wondr Health surveyed 2,095 U.S. adults and found that 68% of employed respondents think women should not be expected to push through menopause symptoms at work. The sentiment is shared by 67% of men and 70%...
New Pharmaceutical Reform Alliance Poll: Americans Agree on One Thing – Rein in Big Pharma
The Pharmaceutical Reform Alliance released a new national poll of 1,524 registered voters showing overwhelming bipartisan support for prescription‑drug pricing reform. Eighty‑nine percent of respondents favor reform, while 68% say drug prices have risen and 94% blame pharmaceutical companies for...
NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324...
NImmune Biopharma presented Phase 1 data for its oral LANCL2 drug NIM‑1324 at Digestive Disease Week, showing safety, tolerability, target engagement and superior efficacy versus existing IBD therapies. The study met all primary and secondary endpoints with no dose‑limiting toxicities and...
Hepta Reveals Blood-Based Epigenetic Signatures of GLP-1 Response, Enabling Precision Medicine in Obesity and MASH
Hepta unveiled a blood‑based cfDNA methylation assay at Digestive Disease Week 2026 that can identify patients who will lose at least 10% of body weight on semaglutide before the first dose. The SAMARA trial showed baseline epigenetic signatures distinguished responders...
NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite
NomosLogic unveiled two consumer‑facing experiences, Lyceum and Odyssey, on its Dendrite Lite platform. Lyceum delivers a personalized genomic‑literacy quiz generated from a user’s own DNA, while Odyssey presents the genome as a seven‑chapter narrative. Both tools leverage NomosLogic’s Hardy Bridge...
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
Edwards Lifesciences released 10‑year results from the COMMENCE aortic trial, confirming that its RESILIA tissue surgical valves retain high durability. At ten years, 97.9% of patients were free from structural valve deterioration and 97.8% avoided reoperation. The data also show...
Incyte Announces FDA Approval of Jakafi XR™ (Ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Incyte announced FDA approval of Jakafi XR, an extended‑release ruxolitinib tablet, for adult intermediate‑ or high‑risk myelofibrosis, hydroxyurea‑intolerant polycythemia vera, and steroid‑refractory acute or chronic graft‑versus‑host disease in patients 12 years and older. The 55 mg once‑daily tablet is bioequivalent to the 25 mg...
Myomo to Report First Quarter 2026 Financial Results on May 7
Myomo Inc., a wearable medical‑robotics firm, announced it will release its first‑quarter 2026 earnings on May 7, 2026, with a conference call at 4:30 p.m. Eastern Time. The call will provide a business update on MyoPro, the only U.S. device that uses...
PACS Group Announces Acquisition in Alaska; New Construction of a Skilled Nursing Community
PACS Group announced that its independently operated subsidiaries have acquired the Ridgeway Senior Living post‑acute care facility in Anchorage, marking the company’s fourth building in Alaska. The deal includes adjacent land slated for a new 150‑bed skilled nursing community, with...
Trividia Health Correction for TRUE METRIX Blood Glucose Monitoring Systems
Trividia Health issued a follow‑up correction on May 1, 2026 for all TRUE METRIX blood‑glucose meters, updating labeling to clarify the E‑5 error code. The company is distributing new product notices to pharmacies, distributors and end users, and urges patients at high risk...
E-Scopics Announces New FDA Clearance for Hepatoscope® With Expanded Capabilities in Managing Liver Disease Complications, Advanced Elastography Imaging Features, and...
E‑Scopics announced FDA clearance for enhancements to its Hepatoscope® platform, adding a dedicated spleen exam workflow and upgraded 2D transient elastography (2DTE) that complies with IEC 63412‑1. The device now runs on macOS laptops with Apple M3 chips and integrates HL7 FHIR R4...
From Resistance Training to Robotic Surgery, New ASBrS Research Points Toward More Personalized Breast Cancer Care
Four studies presented at the American Society of Breast Surgeons meeting highlight a shift toward less invasive, patient‑centered breast cancer care. A three‑month supervised resistance‑training program boosted strength and body composition across lumpectomy, mastectomy and axillary‑dissection patients. Data showed that...
Ardent Health to Participate in the Bank of America 2026 Healthcare Conference
Ardent Health (NYSE: ARDT) announced it will take part in the Bank of America 2026 Healthcare Conference on May 13 in Las Vegas. The company’s senior leadership will appear in a fireside chat at 11:00 a.m. ET, with the session streamed...
Sydnexis to Present New Data From Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
Sydnexis announced it will unveil new subgroup analysis data from the Phase 3 STAR trial of its low‑dose atropine eye drop SYD‑101 at the ARVO 2026 meeting in Denver. The analysis focuses on children with fast‑progressing myopia, a cohort that typically...
Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
Elevance Health announced its annual Care Provider Recognition Program, honoring 45 medical practices and health systems that rank in the top one percent of its roughly 7,200 value‑based care partners. The award spotlights primary‑care providers delivering superior preventive screenings, immunizations,...
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (Plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals announced that Australia’s Therapeutic Goods Administration approved REDEMPLO® (plozasiran), the first siRNA therapy for familial chylomicronemia syndrome (FCS) in the country. The drug, administered subcutaneously every three months, targets apoC‑III to dramatically lower triglycerides. In the Phase 3 PALISADE...